A research team from the University of Cologne has identified a new approach for treating particularly aggressive pancreatic cancer. It makes use of a genetic mutation that allows the immune system to attack the cancer cells again / publication in ‘Nature Communications’

This month’s tip sheet from Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, features a variety of cancer-related story ideas, including a new immunotherapy drug that significantly extends remission and survival in relapsed multiple myeloma, paradoxical mesothelioma findings, new research illuminating how gliomas evolve after treatment, and a profile of cancer survivorship researcher.

The cost of screening people with the rare, inherited cancer-causing condition Li-Fraumeni syndrome (LFS) is roughly nine times lower than that of treatment, researchers have found. This evidence is sufficient to make the case for investing in early genetic testing in tumour risk syndromes, they say, with benefits not just for patients, but also for healthcare systems.

Dr. Dan Landau, the Bibliowicz Family Professor of Medicine, and a member of the Sandra and Edward Meyer Cancer Center and the Englander Institute for Precision Medicine at Weill Cornell Medicine, has received a Lotus Award from the Pershing Square Foundation for research aimed at uncovering new immunotherapy targets in ovarian cancer.

A type of white blood cell in the immune system, known as neutrophils, can make cancer immunotherapy less effective. This is shown in a new study from Karolinska Institutet published in the journal Immunity. The results show that a signalling molecule in the tumour affects neutrophils, reducing the effect of treatment.